GI CANCERS

In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world analysis may change risk stratification in the future.

Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.

Nitika Sharma, MD, explores developments in the esophageal cancer landscape for Esophageal Cancer Awareness Month.

The recent, significant advances for immunotherapy in esophageal and gastroesophageal junction cancer are promising, and oncologists hope it is just the beginning of further improvements in patient outcomes.

Treatment with nivolumab plus chemotherapy was more effective compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma in the CheckMate 649 study.

According to 5-year survival data from the BILCAP study, capecitabine stands up to observation as a treatment strategy for patient with biliary tract cancer.

Several notable trials in colorectal cancer suggest a shift in treatment management, especially in the length of treatment with immunotherapies.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.

Using combination treatments in the concurrent setting with chemotherapy, radiation therapy, or small molecule oncogene and pathway inhibitors may yield positive data in one setting but not another.

Andreana Holowatyj discusses the key takeaway for community oncologists about early-onset appendiceal cancer.

The FDA has accepted for priority review a new drug application for futibatinib seeking approval for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma who harbor FGFR2 gene rearrangement, including gene fusions.

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.

Michael Chuong, MD, discusses the unmet needs for the treatment of inoperable pancreatic cancer.

Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.

There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.

Ryan Sugarman, MD, discusses the design and purpose of the CheckMate 649 trial for gastroesophageal cancers, gastric cancer, and esophageal adenocarcinoma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the phase 1/1b and 2 KRYSTAL-1 trial and his presentation from the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

The developer has announced that half of the patients are now enrolled in the BESPOKE CRC clinical trial.

Cathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.

Following positive early results from the ASPEN-01 clinical trial, the first patient with HER2-positve gastric or gastroesophageal cancer has received the experimental combination of evorpacept, trastuzumab, ramucirumab, and paclitaxel in ASPEN-06.

The phase 3 NuTide:121 study of acelarin was terminated due to failing to meet a primary end point of overall survival benefit.

In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.

TJ-CD4B had been granted orphan drug designation by the FDA for the treatment of patients with gastric cancer, including gastroesophageal junction carcinoma.

In an interview with Targeted Oncology™, Samuel K. Klempner, MD, discussed the promise of DKN-01 and early results from the DisTinGuish trial.